Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

DNA-Based Immunization against Lyssaviruses

Perrin P. · Jacob Y. · Tordo N.

Author affiliations

Laboratoire des Lyssavirus, Institut Pasteur, Paris, France

Related Articles for ""

Intervirology 2000;43:302–311

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: February 28, 2001
Issue release date: February 2001

Number of Print Pages: 10
Number of Figures: 4
Number of Tables: 1

ISSN: 0300-5526 (Print)
eISSN: 1423-0100 (Online)

For additional information: https://www.karger.com/INT

Abstract

Rabies is a fatal encephalomyelitis. Most cases occur in developing countries and are transmitted by dogs. Because of their high cost, cell culture vaccines have not totally replaced the unsafe brain-derived vaccines which are still used in many developing countries. Moreover, there will be a need for vaccines against rabies-related viruses against which classical vaccines are not always effective. DNA vaccines would, therefore, be a valuable alternative for the production of cheaper rabies vaccines against a larger spectrum of viruses. In this review we report published data on DNA-based immunization with sequences encoding rabies and rabies-related virus antigens.

© 2001 S. Karger AG, Basel


References

  1. Dreesen D: A global review of rabies vaccines for human use. Vaccine 1997;15:S2–S6.
  2. Meslin FX, Fishbein D, Matter H: Rationale and prospects for rabies elimination in developping countries; in Rupprecht C (ed): Lyssaviruses. Berlin, Springer, 1994, p 26.
  3. Pastoret PP, Brochier B, Aguilar-Setien A, Blancou J: Vaccination against rabies; in Pastoret P-P, Blancou J, Vannier P, Verschueren C (eds): Veterinary Vaccinology. Amsterdam, Elsevier, 1997, p 616.
  4. Bourhy H, Kissi B, Tordo N: Molecular diversity of the Lyssavirus genus. Virology 1993;194:70–81.
  5. Gould A, Hyatt A, Lunt R, Kattenbelt J, Hengstberger S, Blacksell S: Characterization of a novel lyssavirus isolated from Pteropid bat in Australia. Virus Res 1998;54:165–187.
    External Resources
  6. Wolff J, Malone R, Williams P, Chong W, Acsadi G, Jani A, Felgner P: Direct gene transfer into mouse muscle cells in vivo. Science 1990;247:1465–1468.
  7. Tang D, DeVit M, Johnston S: Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356:152–154.
  8. Donnelly J, Ulmer J, Shiver J, Liu M: DNA vaccines. Annu Rev Immunol 1997;15:617–648.
  9. Kowalczyk D, Ertl H: Immune responses to DNA vaccines. Cell Mol Life Sci 1999;55:751–770.
    External Resources
  10. Wiktor T, Gyorgy E, Schlumberger D, Sokol F, Koprowski H: Antigenic properties of rabies virus components. J Immunol 1973;110:269–276.
    External Resources
  11. Atanasiu P, Tsiang H, Perrin P, Favre S, Sisman J: Extraction d’un antigène soluble (glycoprotéine) par le Triton × 100 à partir d’un vaccin antirabique de culture tissulaire de premier explant. Résultats d’immunisation et pouvoir protecteur. Ann Microbiol (Paris) 1974;125B:539–557.
  12. Xiang Z, Spitalnik S, Tran M, Wunner W, Cheng J, Ertl H: Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 1994;199:132–140.
  13. Ertl H, Verma P, Xiang Z: Plasmid vectors as anti-viral vaccines. DNA vaccines: A new era in vaccinology. Ann NY Acad Sci 1995;772:77–87.
  14. Xiang Z, Spitalnik S, Cheng J, Erikson J, Wojczyk B, Ertl H: Immune responses to nucleic acid vaccines to rabies virus. Virology 1995;209:569–579.
  15. Xiang Z, He Z, Wang Y, Ertl H: The effect of interferon-γ on genetic immunisation. Vaccine 1997;15:896–898.
    External Resources
  16. Xiang Z, Ertl H: Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995;2:129–135.
    External Resources
  17. Ray N, Ewalt L, Lodmell D: Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine 1997;15:892–895.
    External Resources
  18. Lodmell D, Ray N, Ewalt L: Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection. Vaccine 1998;16:115–118.
    External Resources
  19. Bahloul C, Jacob Y, Tordo N, Perrin P: DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine 1998;16:417–425.
    External Resources
  20. Jallet C, Jacob Y, Bahloul C, Drings A, Desmézières E, Tordo N, Perrin P: Chimeric lyssavirus glycoproteins with increased immunological potential. J Virol 1999;73:225–233.
    External Resources
  21. Biswas S, Ashok M, Reddy G, Srinivasan V, Rangarajan P: Evaluation of the protective efficacy of a rabies DNA vaccine in mice using an intracerebral challenge model. Curr Sci 1999;76:1012–1016.
  22. Osorio J, Tomlinson G, Frank R, Haanes E, Rushlow K, Haynes J, Stinchcomb D: Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine 1999;17:1109–1116.
    External Resources
  23. Anilionis A, Wunner W, Curtis P: Structure of the glycoprotein gene in rabies virus. Nature 1981;294:275–278.
  24. Delagneau JF, Perrin P, Atanasiu P: Structure of the rabies virus: Spatial relationships of the proteins G, M1, M2 and N. Ann Virol (Paris) 1981;132E:473–493.
  25. Gaudin Y, Ruigrok R, Tuffereau C, Knossow M, Flamand A: Rabies glycoprotein is a trimer. Virology 1992;187:627–632.
    External Resources
  26. Benmansour A, Leblois H, Coulon P, Tuffereau C, Gaudin Y, Flamand A, Lafay F: Antigenicity of rabies virus glycoprotein. J Virol 1991;65:4198–4203.
    External Resources
  27. Desmézières E, Jacob Y, Saron M-F, Delpeyroux F, Tordo N, Perrin P: Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines. J Gen Virol 1999;80:2343–2351.
  28. Ertl H, Xiang Z: Genetic immunization. Viral Immunol 1996;9:1–9.
    External Resources
  29. Drings A, Jallet C, Chambert B, Tordo N, Perrin P: Is there an advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine? Vaccine 1999;17:1549–1457.
    External Resources
  30. Lodmell D, Ray N, Parnell M, Ewalt L, Hanlon C, Shaddock J, Sanderlin D, Rupprecht C: DNA immunization protect nonhuman primates against rabies virus. Nat Med 1998;4:949–952.
    External Resources
  31. Perrin P, Jacob Y, Aguilar-Setien A, Loza-Rubio E, Jallet C, Desmézières E, Aubert M, Cliquet F, Tordo N: Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine 1999;18:479–486.
  32. Ertl H, Xiang Z: DNA vaccines to rabies virus: Effects of cytokines on the immune response; in Vaccine 96: Molecular Approaches to the Control of Infectious Diseases. New York, Cold Spring Harbor Laboratory Press, 1996, pp 83–86.
  33. Xiang Z, Kwowles B, McCarrick J, Ertl H: Immune effector mechanisms required for protection to rabies virus. Virology 1995;214:398–404.
  34. Wang Y, Xiang Z, Pasquini S, Ertl H: Immune response to neonatal genetic immunization. Virology 1997;228:278–284.
    External Resources
  35. Wang Y, Xiang Z, Pasquini S, Ertl H: Effect of passive immunization or maternally transferred immunity on the antibody response to a genetic vaccine to rabies virus. J Virol 1998;72:1790–1796.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: February 28, 2001
Issue release date: February 2001

Number of Print Pages: 10
Number of Figures: 4
Number of Tables: 1

ISSN: 0300-5526 (Print)
eISSN: 1423-0100 (Online)

For additional information: https://www.karger.com/INT


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.